Abstract Library

#4502 Molecular analysis of non-functioning PanNETs of the alpha lineage reveals new subtypes and mechanisms of progression

Introduction: Most pancreatic neuroendocrine tumours (PanNETs) are non-functioning. Previously, we demonstrated that small, MEN1-only mutated α-like PanNETs can be distinguished from larger ADM (mutated in ATRX, DAXX and MEN1) PanNETs based on epigenetic profiles. ADM PanNETs have shorter disease-free survival and a higher relapse risk. However, their therapeutic responses vary, underscoring group heterogeneity. ADM PanNETs remain insufficiently characterised, with potential subtype-specific progression drivers with implications for treatment choice and clinical outcome.

Conference:

Presenting Author: Avanthay S

Authors: Avanthay S, Di Domenico A, Kirchner P, Bräutigam K, Chouchane A,

Keywords: pancreas, epigenetics, progression, metastasis, DAXX, ATRX, Pan NET,

#4158 Transcriptomic analysis of PanNET tumor progression from microtumor to metastasis in MEN1 patients

Introduction: Pancreatic Neuroendocrine Neoplasms (PanNENs) are a major component the Multiple Endocrine Neoplasia 1 Syndrome (MEN1). Although multiple pancreatic neuroendocrine microtumors (microadenomatosis) are a histomorphological hallmark of MEN1, their molecular status compared to PanNET as well as their metastasis remains unclear.

Conference:

Presenting Author:

Authors: Chouchane A, Kirchner P, Sylvain Maire R, Schiavo Lena M, Falconi M,

Keywords: Microtumor, MEN1, PanNETs, RNAseq, Transcriptomics, Progression,

#3019 Incomplete Peptide Receptor Radionuclide Therapy Courses - Are We Selecting Our Patients Appropriately?

Introduction: As per recommendations, a Peptide Receptor Radionuclide Therapy (PRRT) with Lu-177 DOTATATE course usually consists of 4 cycles. Patients may discontinue a PRRT course early, either due to progression or toxicity. Limited data are available about predictive factors for PRRT early discontinuation.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Julian G

Authors: Gertner J, Groves J, Aziz B, Miah L, Furtado O'Mahony L,

Keywords: prrt,

#1493 Efficacy and Tolerance of a Simplified Combination of Streptozotocine and Epi-adriamycine in Metastatic Foregut Neuroendocrine Tumor (NET). A Pilot Study

Introduction: Since more than 30 years the combination of Adriamycine (A) and Streptozotocine (STZ) is considered as one of the standard chemotherapy regimens (Moertel et al, N Engl J Med 1992, 326 : 519-23) for patients with aggressive grade 2 metastatic pancreatic NET (PNET).

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Hirsch L, Lepère C, Zaanan A, Landi B, Vaillant J,

Keywords: pancreatic NET chemotherapy,

#399 Malignant Carotid Body Tumors (CBTs), Clinical Presentation, Investigations and Their Management

Introduction: Malignant CBTs are rare (incidence 0.012%) and their management is not well settled. We present 2 pts. with malignant CBTs to define their presentation, investigations done and treatment undertaken w/ FU.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Ahmed M, Tuli M, Alsugair A, AlHindi H,

Keywords: carotid body tumors, paraganglioma,